cause difficulties in school and disruptions of family and social relationships as well as diminished quality of life. Children and adolescents with depression are at an increased risk of suicide, which is the third leading cause of death among people aged 15 to 24 and the sixth leading cause of death among those aged 5 to 14. Adolescents suffering from clinical depression are also more likely to suffer from depression in early adulthood.
There is adequate evidence that treating adolescents with selective serotonin reuptake inhibitors (SSRIs), psychotherapy, or combined therapy (SSRIs and psychotherapy) results in decreased clinical depression symptoms. Treating clinically depressed youths with SSRIs is associated with an increased risk of suicidality (suicidal thoughts, preparation, and attempts of suicide) and, therefore, should only be considered if careful clinical supervision is possible.
See "Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force Recommendation Statement," by supported by the Agency for Healthcare Research and Quality, conducts rigorous, impartial assessments of the scientific evidence for the effectiveness of a broad range of clinical preventive services, including screening, counseling, and preventive medications. Its recommendations are considered the gold standard for clinical preventive services. The recommendations and materials for clinicians for these and previous Task Force recommendations are available on the AHRQ Web site at www.ahrq.gov/clinic/uspstf/ uspschdepr.htm. Clinical information is also available from AHRQ's National Guideline Clearinghouse at www.guideline.gov. I In the first paper, RAND researcher Donna Farley, Ph.D., and AHRQ researcher James Battles, Ph.D., describe the purpose for this supplemental issue, as well as the framework and approach to evaluating these patient safety initiatives. Six process evaluation papers take a closer look at the assessment and experiences of AHRQ-funded patient safety projects, information technology initiatives, the AHRQ-sponsored Patient Safety Improvement Corps, and the growth of patient safety partnerships across the United States. The final two papers explore the challenges inherent in measuring safety outcomes and present the overall findings from the 4-year evaluation. Brief summaries of the papers follow. Serving as the Patient Safety Evaluation Center, the RAND Corporation conducted a 4-year evaluation of AHRQ's initiative dealing with diverse patient safety issues and practices. This lead paper describes the Institute of Medicine's (IOM) mandate for this initiative and its evolution to date, as well as the program evaluation methods used to evaluate it. The authors explain the specific components of the Context-InputProcess-Product (CIPP) evaluation model selected by AHRQ, its application to the initiative, and the process of data collection and analysis. As the patient safety initiative has matured over the years, it has moved from basic knowledge development to testing actual practices deemed effective and informing end users about these outcomes.
Sorbero, M. E. S., Ricci, K. A., Lovejoy, S., and others, "Assessment of contributions to patient safety knowledge by the Agency for Healthcare Research and Quality-funded patient safety projects," pp. 646-664.
AHRQ's extensive portfolio of projects has addressed a wide range of patient safety issues, not only in hospitals, but also in other healthcare environments. Most of the projects focus on general patient safety and medication ordering or administration issues. Special populations, such as the elderly and minorities, are adequately included in the portfolio. Projects most often focus on such patient safety actions as the monitoring and reporting of adverse drug events, provider education and awareness, physical environment redesign, and technology innovation to reduce errors. Many of these patient safety projects look at practices that still need more scientific evidence before their effectiveness can be completely determined. The RAND team recommends that AHRQ develop and implement a strategy to make sure project-generated knowledge and results reach front-line health care providers through organizational collaboration and the creation of new learning tools.
Taylor, S. L., Ridgely, M. S., Greenberg, M. D., and others, "Experiences of Agency for Healthcare Research and Quality-funded projects that implemented practices for safer patient care," pp. 665-683.
In this study, RAND researchers interviewed 60 groups who received 1 of 3 types of patient safety grants (original, challenge, and partnership) from AHRQ between 2003 and 2006 . The selfreported data point to a number of similarities in shared experiences of the grantees, particularly when it comes to lessons learned. Key components of successful project implementation include existing partnering organizations, narrowing the project scope, the use of "champion" buy-in, and technical assistance availability. There were also several unexpected challenges, such as time delays, physician buyin, and the actual difficulty in changing staff practices. This study represents one of the first reported evaluations of patient safety implementation projects in the literature.
Damberg, C. L., Ridgely, M. S., Shaw, R., and others, "Adopting information technology to drive improvements in patient safety: Lessons from the Agency for Healthcare Research and Quality health information technology grantees," pp. 684-700.
Electronic health records (EHR), computerized physician order entry (CPOE), and data exchange networks are just some of the ways information technology (IT) is being used to improve patient safety in health care settings. AHRQ has promoted the innovative use of IT in this area by awarding grants totaling $139 million to 104 health IT projects in 2004. This paper looks at the experiences of these projects and the lessons learned from their adoption, implementation, and long-term viability. Overall, the projects represented diverse facilities, geographic locations, and special populations served. The projects use IT to influence decision support and to implement EHR and CPOE. Important factors linked to the success of implementing patient safety IT projects were identified. These include end-user engagement, adequate pilot testing, effective communication, good leadership, and available training opportunities. The majority of grantees felt strongly that their gains in knowledge and implemented systems could be successfully replicated by other institutions.
Patient safety initiatives
continued from page 3 coming away with valuable skills and the confidence to use them in their health care settings. They continued to use these effective patient safety interventions even after 2 years had passed since receiving the training. Its impact reached well beyond the immediate health care environment to affect patient safety actions made by state agencies in the form of legislation and oversight procedures. Following their training, participants became effective trainers of others at their institutions. Despite training approximately 250 individuals, the PSIC needs to strengthen and expand this network in order to create long-term improvements in patient safety practices and outcomes. Continued training of new participants as well as postgraduate modules for former trainees will help.
Mendel, P., Damberg C. L., Sorbero, M. E. S., and others, "The growth of partnerships to support patient safety practice adoption," pp. 717-738.
Part of RAND's evaluation of AHRQ's patient safety initiative also included a critical look at the formation of organizational partnerships at the national level. In this study, researchers conducted two rounds of telephone interviews with 35 organizations in 2004 and 55 in 2006. These key organizations were found to be engaged in interorganizational partnerships of various sizes and reach. Over the time period, there was a considerable increase in notable activities, particularly the dissemination of patient safety information and the development of practical tools. Partnership network fragmentation decreased while network centralization increased. The researchers found that AHRQ was centrally positioned within these partnerships to be a leader in these activities. As patient safety partnerships of all types continue to grow and expand, AHRQ's central role in these collaborations ensures the ongoing creation and dissemination of tools and practices. In the concluding article, overall findings are summarized from the 4-year RAND evaluation. The researchers conducted interviews with AHRQ staff, its grantees, and other patient safety parties. They also reviewed materials published by AHRQ and various internal documents. During the period from 2001 through 2006, AHRQ made strong progress in developing new knowledge on patient safety epidemiology and practices. There was also a strengthening of infrastructure in order to support the adoption of safe practices among health care providers at the institutional level. Only limited progress was made in AHRQ's ability to create a monitoring and vigilance capability. Divergent views among stakeholders and lack of consensus have hampered the development of a national monitoring capability. According to those interviewed, the lack of engaged health care leadership and continued denial of safety issues within the health care community are just some of the reasons why progress remains frustratingly slow. Along with being grateful to AHRQ for its work to date on patient safety despite limited resources, stakeholders suggest that it work harder at getting evidence-based practices adopted by front-line providers. Partnering with other organizations may help with efficient and timely dissemination.
Greenberg
Editor's note: A limited number of copies of the HSR theme issue (AHRQ publication no. OM09-0059) are available from AHRQ.* I A new study of the usefulness of hospital reports on patient safety incidents finds that most of the report narratives helped identify factors that contributed to the incident. However, each category of factors (patient, system, and provider factors) was identified in only a minority of the incident reports, and often little detail was provided about provider factors. The researchers conclude that strategies for obtaining narrative descriptions with more details are needed for incident reports to be truly useful in improving patient safety.
At least one contributing factor was identified in 80 percent of reports, with many reports identifying several contributing factors. Patient factors and system factors each showed up in 32 percent of the reports, while provider factors could be noted in 46 percent of the reports. Most of the patient factors were classifiable into subtypes, with the underlying illness being the most common (61 percent of the reports with patient factors). Personnel issues (primarily teamwork and availability of staff) and physical environment issues (unavailability or malfunction of a facility, device, or medicine) were the most common system factors identified. Only slightly more than half of the provider factors could be subclassified; the most common provider factors were slips or lapses, both reflecting unconscious errors.
The researchers examined 2,228 incident reports collected in 2001 by voluntary, but not anonymous, reporting systems at a teaching hospital and an affiliated community hospital in a major metropolitan area. These reports were sampled so that the patients involved would be representative of the 2001 patient population at the two hospitals. Results were adjusted for the number of patients with more than one hospital admission during the calendar year. The study was supported, in part, by the Agency for Healthcare Research and Quality (HS11512).
More Hospital reports on patient safety incidents can be useful in identifying the contributing factors, but often need more detail A n average of 2.3 medications are prescribed during each physician office visit. One risk associated with the use of multiple medications is the possibility of potentially dangerous drug-drug interactions (DDIs).
DDIs can lead to an emergency department visit, admission to the hospital, and sometimes death. Yet, 950 clinicians in a recent survey correctly identified only 43 percent of drug pairs with potential DDIs. This suggests that prescribers' knowledge of potentially clinically significant DDIs is generally poor, conclude the researchers at the University of Arizona and the Arizona Center for Education and Research on Therapeutics (CERT).
They mailed a questionnaire to a national sample of 12,500 prescribers who were selected on the basis of a past history of prescribing drugs associated with known potential for DDI. Recipients were asked to classify 14 drug pairs as "contraindicated," "may be used together but with monitoring," or "no interaction." They could also state that they were "not sure."
The 950 responding prescribers classified 42.7 percent of all drug combinations correctly. Correct classification of specific drug pairs ranged from 18.2 percent for warfarin and cimetidine to 81.2 percent for acetaminophen with codeine and amoxicillin. The number of drug pairs correctly classified by individual prescribers ranged from 0 to 13. For half of the drug pairs, over one-third of the respondents answered that they were "not sure," and two of these drug pairs were contraindicated. One- 
Visit the AHRQ Patient Safety Network Web Site
AHRQ's national Web site-the AHRQ Patient Safety Network, or AHRQ PSNet-continues to be a valuable gateway to resources for improving patient safety and preventing medical errors and is the first comprehensive effort to help health care providers, administrators, and consumers learn about all aspects of patient safety. The Web site includes summaries of tools and findings related to patient safety research, information on upcoming meetings and conferences, and annotated links to articles, books, and reports. Readers can customize the site around their unique interests and needs through the Web site's unique "My PSNet" feature. To visit the AHRQ PSNet Web site, go to http://psnet.ahrq.gov/.
A ccurate assessment of kidney (renal) function can help clinicians prescribe medication dosages that are less likely to cause adverse drug events (ADEs), according to a new study. Many medications are excreted via the kidney, so that impaired kidney function can lead to increased blood levels or prolonged retention of medications because of slowed removal from the body, with sometimes toxic results. To help avoid ADEs in patients with high or hidden risk of impaired kidney function, the researchers recommend that nurses routinely assess patient levels of creatinine in the blood and estimated rates of creatinine clearance, which are used together as measures of kidney function.
They collected information on 1,052 medication safety events (both actual and potential ADEs) including 318 medication errors reported on 17 clinical units at 2 urban, nonteaching community hospitals before the implementation of a commercial computerized physician order entry (CPOE) system. The researchers estimated creatinine clearance and used laboratory measurement of serum creatinine to classify each patient as being of high (144 patients), hidden (81 patients), or low (93 patients) risk of kidney-related medication events. High-risk patients had high levels of serum creatinine and low clearance rates, low-risk patients had low serum creatinine and high clearance rates, while hidden-risk patients had a combination of low serum creatinine and low clearance rates.
Age and sex were each significantly associated with renal risk groups: patients over 80 years old formed the largest group for hidden risk, while men were the largest group at high risk and more women than men had hidden risk. A third of the reported medication errors occurred in patients under 65 years old, a third in patients between ages 65 and 79 years, and a third among patients 80 years or older. Medication errors among patients with high or hidden risk of renal insufficiency primarily occurred during ordering or transcription of the order, and most often involved a wrong dose rather than wrong drug choice or frequency of administration. The researchers found that antibiotics accounted for a fourth and diabetes drugs accounted for a sixth of medication errors. Antibiotics accounted for more than a third of the errors in the high-risk group and less than a fifth of errors for the hidden-risk and normal-risk groups. The study, which is part of a larger study of the impact of CPOE systems on the outcome of ADEs, was funded in part by the Agency for Healthcare Research and Quality (HS13131).
More Lack of resources and time, along with staff burnout, are barriers to sustaining quality improvement in community health centers W hen a surgeon or oncologist talks with a newly diagnosed lung cancer patient, the physician often misses many chances to provide emotional support to the patient. Instead of noting and addressing the patient's worries and concerns, the physician often responds to patient concerns by talking about biomedical aspects of cancer diagnosis or treatment, a new study reports.
Based on the researchers' analysis of transcripts of 20 patient-doctor consultations concerning newly diagnosed lung cancer, researchers identified 384 empathic opportunities, but found that physicians provided empathic responses to only 39 (10 percent) of them. Half of the physicians' expressions of empathy occurred toward the end of the consultations with the patients, despite chances to provide such emotional support throughout the discussion. Physicians responded with empathy most often to opportunities involving health care system issues (23 percent) or statements about difficulty in making treatment decisions (21 percent). Less than 10 percent of the empathic responses from physicians addressed patient concerns about symptoms and death related to the diagnosed cancer, although these were the concerns raised most frequently by patients.
The researchers suggest that their findings can be used to improve physicians' empathic responses, especially when communicating with patients who have a life-threatening illness. They suggest that physicians can offer empathy earlier and at intervals during their conversations with patients, and that such encounters could be brief while still helping to build rapport and trust. The study was supported in part by the Agency for Healthcare Research and Quality (HS10876).
Additional information can be found in "Missed opportunities for interval empathy in lung Women's Health A fter surgery, women diagnosed with early stage breast cancer often benefit from treatment with chemotherapy, radiation, or hormonal therapy. For this reason, surgeons typically refer these patients to oncologists. Unfortunately, some women, especially blacks and Hispanics, are not seen by the oncologist, though their surgeons assume they are. To keep these women from falling through the cracks, New York researchers developed a tracking system to find out if patients visited an oncologist and feed that information back to the surgeon so they could follow up with patients who did not connect with oncologists. Researchers compared the treatment of 639 women with early stage breast cancer who were seen at 6 New York City hospitals between January 1999 and December 2000 with 300 women who were seen between September 2004 and March 2006, the time period in which the tracking system was used.
Rates of oncology consultations, chemotherapy, and hormonal therapy were higher for all women after the tracking system was in place. The authors state that their tracking system eliminated the racial disparity that existed for black and Hispanic women regarding the underuse of radiation, chemotherapy, and hormonal therapy. For example, after the tracking system was implemented, underuse of radiotherapy declined from 23 to 10 percent, underuse of chemotherapy decreased from 26 to 6 percent, and underuse of hormonal therapy diminished from 27 to 11 percent for black and Hispanic women.
The authors suggest two ways to ensure patients receive proper care for early stage breast cancer. The first is by ensuring tumor registry personnel follow up with patients to determine if they visited oncologists. The second is having insurers require an oncology consultation for all patients diagnosed with invasive breast cancer to make sure these women receive appropriate treatment. This study was funded in part by the Agency for Healthcare Research and Quality (HS10859).
See "A tracking and feedback registry to reduce racial disparities in breast cancer care," by Nina A. Tracking system ensures women with breast cancer see oncologists and receive additional treatment A woman's likelihood of developing colorectal cancer also increases when her father, mother, or sibling develops that cancer. However, a new study finds that this increased risk for colorectal cancer does not negatively affect the woman's survival rate if she develops it.
Researchers tracked 1,391 women who were diagnosed with invasive colon cancer in Wisconsin. Of the 262 women with a family history of colon cancer, 44 died of the disease. In contrast, of the 1,129 women who had no family history of the disease, 224 died. Women who had two or more relatives with colorectal cancer appeared to have a lower risk of dying from the disease compared with women who had no family history of the cancer. Thus, inherited colorectal cancer may have better survival rates than sporadic cancers, the authors suggest.
Determining a family history of colorectal cancer is seen as a cost-effective way to identify an individual who may be at risk for developing it. These findings indicate that awareness of a family history of the disease may also serve as a clinical tool after diagnosis because of the variation in survival rates between those with and without a family history of colorectal cancer. This study was funded in part by the Agency for Healthcare Research and Quality (HS13853).
See "Family history and colorectal cancer survival in women," by Anne C. Kirchhoff, M.P.H., Polly A. Newcomb, Ph.D., M.P.H., Amy Trentham-Dietz, Ph.D., and others in the 2008 Familial Cancer 7(4), pp. 287-292. I
Women with a family history of colon cancer have good survival rates when diagnosed with that cancer
Health Information Technology C omputerized prescriber order entry (CPOE) systems allow clinicians to electronically enter medication orders. These systems can reduce medicationrelated errors because they eliminate the need to decipher handwriting, improve communication between providers, and standardize care. When a clinical decision support system (CDSS) is added to a CPOE, it provides the added value of integrating a medical knowledge base, patient data, and an inference engine to generate drug alerts on the case at hand.
To determine the cost of developing a CDSS, researchers studied a team that developed one at a long-term care facility in Canada. Patients in these facilities often have weakened kidney function and take multiple medications, which puts them at a high-risk of medication-caused health problems. The team created 94 alerts for recommended maximum doses of 62 medications that could be prescribed to patients with weakened kidneys.
The cost of personnel to develop the CDSS was $48,178 and 925 hours. Physicians logged the most hours (390) to prepare the detailed content, and pharmacists contributed 180 hours preparing content and testing the drug alerts. The costs were lowered since users were familiar with prescribing alerts, thus very little time was required to train and support users. The researchers estimated that if an off-the-shelf renal dosing CDSS were available, it could have reduced the total cost by $24,483. However, the staff would still spend 241 hours evaluating the system and its alerts, because commercial companies tend to be conservative and include too many, rather than too few, alerts to avoid liability as well as to ensure that the alerts are consistent with local clinical practice. Hence, physicians and pharmacists would likely need to spend time editing alerts and deactivating those that are considered extraneous. Researchers also estimated that if a database with dosing recommendations for patients with weakened kidneys were available and could be used with a CPOE, it could cut the cost by $13,977. This study was funded in part by the Agency for Healthcare Research and Quality (HS10481 and HS15430) .
See "Costs associated with developing and implementing a computerized clinical decision support system for medication dosing for patients with renal insufficiency in the long-term Clinical decision support systems are costly to develop and rely heavily on physician and pharmacist expertise M assachusetts physicians in practices with electronic health records (EHRs) were significantly less likely to have a history of paid malpractice claims than physicians without access to EHR systems, according to a new study. However, after adjusting for factors such as sex, race, year of medical school graduation, and practice specialty, these findings were suggestive but not conclusive, the researchers said. Future studies should include information on when the physicians adopted an EHR, along with the date of any malpractice incident, the filing date of the lawsuit against them, and when it was settled. This would allow researchers to determine definitively whether or not an EHR was in use at the time of the incident.
The study, a survey of 1,345 randomly selected Massachusetts physicians, found that 6.1 percent of the physicians with EHRs had a history of paid malpractice claims versus 10.8 percent for those without EHRs. Overall, 33 percent of the responding physicians used EHRs in their practices. These physicians tended to be younger and less likely to be in solo practices than those not using EHRs. Physicians in solo practice were significantly more likely to have paid malpractice claims than physicians in practices with 10 or more physicians, even after adjusting for other factors.
Physicians who did not see outpatients or who did not have physician profiles on the Board of Registration in Medicine (BRM) Web site (which lists 
Malpractice claims
continued from page 9 malpractice claims paid within the last 10 years) were excluded, because data on whether participants had paid malpractice claims was collected from the BRM Web site. The study was funded in part by the Agency for Healthcare Research and Quality (HS15397).
More details are in "Electronic health records and malpractice claims in office practice," by Anunta Virapongse, M.D., M. Outcomes/Effectiveness Research P atients age 65 and older with heart disease who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by the Agency for Healthcare Research and Quality (AHRQ) and the American College of Cardiology's National Cardiovascular Data Registry.
The comparative effectiveness study of 262,700 Medicare patients who received stents-spring-like tubes to keep heart vessels open-is the largest ever to compare drug-coated stents with bare metal ones. Researchers from Duke University, AHRQ, and Kaiser Permanente found that, compared with patients who received bare metal stents, those fitted with stents coated with medication (called drug-eluting stents) had an 18 percent better survival rate over the 30-month study period and were 16 percent less likely to suffer a heart attack.
The researchers found that 16.5 percent of the patients implanted with bare metal stents died within 30 months of implantation, compared with 13.5 percent of those with drug-eluting stents, after adjusting for population differences. They also found that 8.9 percent of the patients with bare metal stents suffered heart attacks during the period, compared with 7.5 percent of those with drug-eluting stents-a 16 percent higher rate. The researchers further found that patients fitted with drug-eluting stents in 2005 and 2006 had a lower risk of death than those given the stents in 2004.
According to AHRQ's Art Sedrakyan, M.D., Ph.D., a coauthor of the study, better outcomes found for patients with drug-eluting stents may be partially explained because those patients are required to take blood-thinning drugs, such as clopidogrel, for a long time after their procedure. Patients who receive bare metal stents are usually prescribed blood-thinner medications for a shorter period of time and may take them less often. In addition, patients with drug-eluting stents may visit their doctors more often after hospital discharge and may receive prescriptions for drugs and therapies to lower their cholesterol levels and manage other heart conditions more often than patients who received bare metal stents.
The researchers based their study on data from the American College of Cardiology's National Cardiovascular Data Registry on patients who underwent angioplasty with drug-eluting or bare metal stent implantation at 650 hospitals, together with Medicare national claims data to capture posthospital discharge information. The authors call for longer followup studies to further support the study's results and to confirm the possible effects of postimplantation treatment with blood-thinning drugs such as clopidogrel.
See Patients with drug-coated stent implants have a lower risk of death and heart attack when compared with patients who receive bare metal stents A new study finds that use of cardiac resynchronization therapy (CRT), a treatment recommended for many patients hospitalized for congestive heart failure (CHF), varies. Patients with CHF commonly suffer from lack of coordinated contraction of their right and left ventricles. Such coordination is needed for proper movement of blood to the body, including the lungs. An implantable CRT device, much like a cardiac pacemaker, restores the coordination by stimulating both ventricles at the same time, as well as restoring the proper rhythm to the contraction of the right atrium and right ventricle. The study finds that the use of this treatment varies depending on the patients' race, what part of the country they live in, other health problems, and their age. Further studies and the use of quality-of-care initiatives may help address these gaps in treatment, the researchers conclude.
The study analyzed data on 33,888 patients with CHF who were admitted over a 2-year period to 228 hospitals participating in an American Heart Association program to improve the treatment of this condition. The researchers found that 12 percent of these patients were discharged with CRT. The CRT patients were older than CHF patients not given CRT (70 percent of the CRT patients were Medicare beneficiaries), more likely to be white than black or of other races, had higher rates of kidney problems, and more than half had restricted blood flow to the heart muscle (ischemic cardiomyopathy).
continued on page 12
Use of a new heart failure therapy that resynchronizes contraction of ventricles varies A new study of outcomes for elderly patients with heart failure who received implanted mechanical heart pumps (ventricular assist devices, or VADs) to support their circulation finds that many patients still die during or shortly after surgery. Many of the survivors are readmitted to the hospital within 6 months, and treatment costs remain high. The researchers conclude that improving patient selection, to reduce deaths during and shortly after surgery, is important to improve overall outcomes.
Researchers examined claims from Medicare patients in fee-forservice plans over a 6-year period. Overall, 2,943 patients at 570 hospitals received VADs. Half of the patients had not had prior openheart surgery (the primary device group), while half had undergone open-heart surgery within 30 days before VAD implantation (the postcardiotomy group). Few of the hospitals performed more than 5 device implants annually (ranging from 19 hospitals in the year 2000 to 28 in the year 2005).
For all years, 815 patients (55.2 percent) in the primary device group were discharged alive from the hospital with a VAD, while 140 (9.5 percent) received heart transplants and 455 (30.8 percent) died during their hospital stay. At 1 year after implantation of the VAD, 417 primary device patients (32.2 percent) were still alive with the device, 299 (20.7 percent) had received a heart transplant, and 617 (42.2 percent) had died. Among the patients with prior open-heart surgery, 493 patients (33.6 percent) were discharged live with a VAD, 21 (1.4 percent) underwent a heart transplant, and 824 patients (56.2 percent) died during their hospital stay. At 1 year of followup, 333 postcardiotomy patients (24.1 percent) were alive with a VAD implanted, 51 patients (3.5 percent) had received heart transplants, and 929 (63.4 percent) had died.
The researchers used retrospective data on all Medicare fee-for-service patients receiving VADs, so the study provided a complete picture of the use of mechanical heart assist devices outside of clinical trials. They did not observe improved outcomes for prior cardiotomy patients from the beginning to the end of the study period, but saw a decline in 1-year survival from 41 percent in the year 2000 to 22 percent by 2006. The researchers suggest that this decline in survival may represent an increase over time in patients who would not have previously been considered for the procedure receiving VAD implants. The study was funded in part by the Agency for Healthcare Research and Quality (HS16964).
More details are in "Long-term outcomes and costs of ventricular assist devices among 
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Heart failure therapy continued from page 11
The likelihood of a patient receiving a new CRT implant was lower for patients living in the northeastern States, of black race, and older than 70 years. In contrast to studies of patients receiving another kind of cardiovascular device (implantable cardioverterdefibrillators), black women and black men were equally likely to receive new CRT devices. The study was funded in part by the Agency for Healthcare Research and Quality (HS16964).
More details are in "Use of cardiac resynchronization therapy in patients hospitalized with heart failure," by Jonathan P. In evaluating patients with sore throat, the principal goal is identifying patients likely to have GABHS. Only 5 to 15 percent of adult patients seeking care for sore throat are likely to have GABHS. The clinical scoring algorithm known as the "Centor Criteria" consist of four findings that are each assigned one point: history of fever, absence of cough, tender or swollen lymph glands in the neck, and red and swollen tonsils. These criteria are easy to implement and accurately stratify adult patients with suspected GABHS. A lthough diabetes-related damage to organs such as the kidneys and eyes is well recognized, diabetes also causes functional decline, depression, pain, and lost productivity. The good news is that telephone support from nurses on how to self-manage diabetes can improve patients' functioning and help them gain qualityadjusted life years (QALYs). A group of University of California, San Francisco researchers compared the cost effectiveness of automated telephone self-management (ATSM) plus nurse care management among 112 primary care patients with diabetes in 4 safety net clinics with usual care received by 114 similar patients.
ATSM used interactive phone technology to provide surveillance, patient education, and one-on-one counseling, and was implemented in languages for a 9-month period using a randomized control trial design. The per-patient cost to achieve a 10 percent increase in the proportion of ATSM patients meeting American Diabetes Association exercise guidelines was estimated to be $558 for all costs and $277 for ongoing costs alone.
The annual cost of the ATSM intervention per QALY gained, relative to usual care, was $65,167 for start-up and ongoing implementation costs combined, and $32,333 for ongoing implementation costs alone. This is a cost-effectiveness similar to that of other accepted diabetes interventions related to medication intensification (for example, $35,300 per QALY gained for intensive glucose control) and diabetes case management ($44,941 per QALY gained). The study was supported in part by the Agency for Healthcare Research and Quality (HS14864 and HS17261).
continued on page 14
Telephone nurse support can be cost-effective to help improve functioning and quality of life for patients with diabetes A ntibiotics offer no help for acute respiratory tract infections (ARI) that are caused by viruses. Distinguishing which ARIs are caused by viruses and bacteria is primarily based on clinical examination, rather than a diagnostic test result. Practice guidelines have been developed by a variety of organizations to help clinicians distinguish viral vs. bacterial ARIs. According to a new study, the duration of illness appears to influence practitioners the most in deciding when to use antibiotics for ARI, particularly when the patient also has a fever or productive cough.
Researchers presented 101 primary care physicians, nurse practitioners, and physician assistants with a set of 20 patient vignettes describing patients with ARI symptoms. Practitioners indicated they would prescribe antibiotics in 44.5 percent of the cases presented to them. On a scale from 0 to 100, their comfort level in making this decision was 78. When asked how strongly they would urge the patient to take antibiotics, their rating was 24. Among the variables in deciding when to use an antibiotic, duration of illness was deemed most important by 72 percent of the practitioners. This was the strongest decisionmaker for antibiotic use when it was accompanied by fever or productive cough.
The researchers also asked 8 internal medicine faculty to review published expert-panel guidelines from the CDC on managing ARI and then rate the same 20 cases. These clinicians prescribed antibiotics in only 20 percent of the cases, believing that 19.4 percent of them were bacterial in nature. The researchers indicate that eliminating the effect of a productive cough in the first set of practitioners studied would bring their prescription rate close to that of the faculty members. Educational programs that target the use of antibiotics in relation to specific symptoms may help practitioners avoid overprescribing. The study was supported by the Agency for Healthcare Research and Quality (HS13001 The researchers examined data from 57 primary care practicebased research networks who implemented the CCM. The relationship between the CCM and three health measures-general health status, unhealthy days, and activity-limiting days-were examined.
General health status was found to vary significantly across CCM elements such as organization of care, self-management support for behavior change, delivery system design, integration of decision support, use of clinical information systems, and community resources. Significant relationships were identified for almost all CCM components and both unhealthy and activity-limiting days. Patients who received care from practices that supported behavior change were nearly twice as likely to have better health status than patients in practices that were hospital/ university health system-owned, used group/individual planned visits for prevention, or PDAs for clinician-decision support. Practices that used patient registries, health promotion champions, and evidence-based guidelines for treating risk behaviors had patients with fewer unhealthy or activitylimiting days compared with practices that used group/individual planned visits for prevention and patient reminder cards.
These findings reinforce the idea that organizational characteristics can influence patient health outcomes, according to the researchers. The study was supported in part by the Agency for Healthcare Research and Quality (HS17007 Use of a chronic care model framework in primary care practices can influence patient health status S tudies of geographically diverse American Indian tribes consistently show low levels of leisure-time physical activity, less frequent exercise, and a higher proportion being classified as sedentary. Researchers led by Craig N. Sawchuk, Ph.D., of the University of Washington found that physical activity among American Indian elders (aged 50-74) can be promoted in a brief, inexpensive manner in primary care. The study randomly divided 125 American Indians into 2 groups, with the first group receiving basic instruction in daily physical activity monitoring and the second group receiving instruction in daily physical activity monitoring augmented with a pedometer to track and record their total daily step counts. At the end of the 6-week study, participant fitness was measured by performance in a 6-minute walk test. Both groups showed increases in walking frequency.
Contrary to the researchers' initial hypothesis, adding a pedometer to daily physical activity monitoring did not produce an increase in self-reported physical activity scores. The finding that a pedometer continued on page 15
Simple, effective methods to promote increased physical activity introduced to older American Indians in a primary care setting yield positive results
American Indians continued from page 14
did not confer an advantage over basic self-monitoring suggests that self-monitoring alone may be sufficient. This conclusion may be premature, however, given that participants using pedometers were not offered any instruction in daily step-count goal setting. The researchers further suggest that the act of selfmonitoring can raise awareness of modifiable health habits, create an external environmental reminder to increase personal responsibility, improve self-efficacy, and provide ongoing feedback on progress.
The study included two face-to-face 60-90 minute clinic sessions with the research assistant at the beginning and end of the study period. There were also two 10-minute phone calls during weeks two and four to reinforce participation in the study. During the initial session, the research assistant reviewed different types of physical activity and distributed an educational handout on the health benefits of increased physical activity. The study was supported by the Agency for Healthcare Quality and Research (HS10854).
See "A randomized trial to increase physical activity among native elders" by Dr. Sawchuk, Steve Charles, Yang Wen, M.S., and others in Preventive Medicine 47, pp. [89] [90] [91] [92] [93] [94] 2008 . I A lthough asthma is a common disease, rates are particularly high among minorities who live in inner-city neighborhoods. For example, East Harlem in New York City has hospitalization and mortality rates that are several times the national average. Yet, several barriers prevent health care providers in these areas from adhering to national asthma guidelines.
Researchers surveyed 202 primary care providers working in East Harlem at 3 large general medicine clinics located in hospitals and 1 large communitybased practice. Specific questions addressed the provider's adherence to 5 asthma management practices recommended in guidelines developed by the National Heart, Lung, and Blood Institute (NHLBI): use of inhaled corticosteroids, peak flow monitoring, asthma action plans, allergy testing referrals, and influenza vaccination.
Among the providers surveyed, 70 percent were aware of the NHLBI guidelines. However, only 39 percent had actually read them, and 46 percent were using them to manage their asthma patients. Adherence to specific recommendations was highest for influenza vaccination (73 percent), the use of inhaled corticosteroids (62 percent), and peak flow monitoring (34 percent). There was little adherence among providers when it came to using asthma action plans (9 percent) and referring patients for allergy testing (10 percent).
The researchers also found several barriers that were significantly associated with poor adherence to the guidelines overall. One of the most important was the lack of self-efficacy among providers. Providers felt they did not have the ability or confidence to execute specific guideline recommendations. Other barriers included not being fully familiar with the guidelines and the expectation that patients would not adhere to the various activities called for.
The researchers indicate that increased efforts are needed to bridge the gap between actual care and knowledge of the recommendations. The study was supported in part by the Agency for Healthcare Research and Quality (HS13312).
See "Barriers to adherence to asthma management guidelines among inner-city primary care providers," by Juan P. Researchers at the Centers for Education and Research Therapeutics (CERT) at the University of Pennsylvania School of Medicine studied 3,134 patients who received a course of oral levofloxacin for 3 days or longer. For 895 patients, a DTCC was coadministered with 100 percent of levofloxacin doses. A levofloxacin-resistant isolate was identified in 198 patients (6.3 percent) after receiving a course of levofloxacin treatment. These organisms were of several types such as Staphylococcus aureus and Klebsiella pneumoniae. Coadministration of DTCCs was significantly associated with subsequent identification of a levofloxacin-resistant isolate.
It is recommended that DTCCs be given at least 3 hours before or after giving oral levofloxacin. Yet, at the study hospitals, if a patient was administered levofloxacin and a DTCC on the same day, the two medications were given within 2 hours of each other 77 percent of the time (also known as coadministration). Whether prescribers are unaware of the interactions between DTCC and fluoroquinolones or simply do not know the potential ramifications of coadministration is unknown. The study authors recommend that whenever possible, coadministration of DTCCs and fluoroquinolones should be avoided completely.
The study was supported in part by the Agency for Healthcare Research and Quality (HS10399). Giving patients drugs that interfere with fluoroquinolone antibiotic absorption may lead to resistant infections S tudies have shown that patients who take certain beta-blockers for heart failure have improved survival rates. However, not all betablockers have been tested to treat heart failure. Three beta-blockerscarvedilol (CoReg), metoprolol succinate (Toprol XL), and bisoprolol fumarate (Zebeta)-are referred to as evidence-based beta blockers (EBBBs) because they have been tested for patients with heart failure. However, a new study finds that elderly patients prescribed either EBBBs or non-EBBBs after hospitalizations for heart failure have similar survival rates.
Judith M. Kramer, M.D., M.S., of Duke University, and her colleagues found that patients hospitalized with heart failure who took EBBBs had a 24-percent mortality rate 1 year after their hospitalizations. Those who took non-EBBBs had a 23-percent mortality rate. In contrast, patients who received no beta-blockers had a 28-percent mortality rate. Nearly 60 percent of patients received no beta blockers. The authors note that physicians who fail to prescribe beta blockers and patients who fail to take them may contribute to higher mortality rates from heart failure.
In the year following their hospitalizations for heart failure, patients who took EBBBs were rehospitalized more often than patients taking non-EBBBs or no beta blockers. These rehospitalizations may have occurred because the patients had other risks for rehospitalization or had physicians who provided better quality care and readmitted the patients to monitor them, the authors suggest.
Because patients were not randomly assigned to receive EBBBs or non-EBBBs, the authors caution that the findings need to be replicated. This study of 11,959 patients eligible for Medicare and Medicaid in North Carolina was funded in part by a grant from the continued on page 17
Patients who suffer heart failure do well if they take any betablocker rather than only those extensively tested for the condition Researchers reached this conclusion after a review of the research ethics literature, consultation with a health plan ethics committee, interviews with patients, physicians, and health plan leaders, and their own ethical deliberations. They envision that physicians participating in the CRT would provide either drug A or drug B for a particular condition such as hypertension, which are both considered effective for that condition. Neither drug is considered "better" than the other (clinical equipoise).
Several health plans will participate with some favoring A and others favoring B. "Favor" means that unless clinicians have specific reasons for choosing the nonpreferred agent, they will use the preferred one. Health plan databases will be used to follow patterns of side effects, medication changes, and clinical outcomes.
Since the choice of drug A or B mimics clinical practice pretty closely, and the drugs are both effective, there is no need to get patient's consent in any way that differs from ordinary practice, note the researchers. However, there is a need to show respect for patients by treating them as research partners and explaining the existence of the CRT and rationale for conducting it. Study explores the ethics of using cluster randomized trials to compare drug effectiveness A fter drugs go through rigorous clinical trials for determination of safety and efficacy, the U.S. Food and Drug Administration (FDA) approves the product and allows it to be labeled and marketed to treat specific conditions. Some clinicians, however, prescribe drugs to treat conditions for which they have not been approved. This practice, called "off-label" prescribing is allowed as part of the practice of medicine. However, in some cases there is little or no evidence as to the effectiveness or safety of this off-label use.
Surrey M. Walton, Ph.D., and colleagues at the Chicago-Area Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Center, under an Agency for Healthcare Research and Quality contract (290-2005-0038 ), developed a model to prioritize research on drugs currently being used off-label. The model applies quantitative measures of the absolute number of off-label uses for a drug, the scientific evidence for the drugs' off-label use, safety concerns, marketing activity, longevity, and drug cost.
The researchers identified 14 drugs, mainly antidepressants and antipsychotics, that were most worthy of further research, such as systematic comparisons of the available evidence. For instance, the atypical antipsychotics quetiapine, risperidone, and olanzapine are all approved to treat schizophrenia. 
HIV/AIDS Research
Off-label prescribing continued from page 17 However, they are also commonly prescribed off label to treat bipolar disorder and depression, even though the FDA has approved quetiapine and risperidone only for when a patient with bipolar disorder is experiencing a manic or depressive episode.
The authors recommend policymakers place a greater emphasis on comparative effectiveness studies for these offlabel uses and require greater scrutiny of marketing efforts that encourage physicians to prescribe drugs off label. Finally, policymakers could call for diagnosis to become part of the prescription record to facilitate comparative effectiveness research of off-label uses. Electronic health records that capture documentation of a diagnosis for every prescribed drug could be useful tools in that F or treatment to succeed, patients with HIV infection must strictly adhere to their highly active antiretroviral therapy (HAART). If they do not, treatment failure (also called virological failure) occurs, which means that HIV increases in the blood to detectable levels and often it is a resistant strain that is harder to treat. A new study finds that the window between when patients stop adhering to an efavirenzbased HAART regimen and onset of virological failure can be as long as 90 days. This presents a window of opportunity for clinicians to take action as soon as nonadherence is detected, to prevent virological failure and maintain HIV suppression, suggest the study authors.
Investigators from the Center for Education and Research on Therapeutics (CERT) at the University of Pennsylvania School of Medicine and colleagues observed 116 adults with HIV infection with virological suppression (undetectable HIV RNA in the blood) on efavirenz-based HAART. Patients were seen each month and the study was stopped either at virological failure (more than 1,000 copies of HIV RNA/mL of blood) or 12 months, whichever came first. They used a monitoring system to measure the percentage of HAART doses taken during the study period. The results were summarized in four 90-day adherence periods: immediately, 30 days, 60 days, or 90 days prior to virological failure.
HAART adherence was significantly lower for the seven patients with virological failure compared with the other 109 without virological failure. These differences were significant even up to 90 days prior to the virological failure date (57 percent adherence in the failure group vs. 95 percent in the nonfailure group). The study demonstrates the flaw in assuming that all HIV patients with undetectable viral loads are adherent and therefore should be encouraged to "keep doing what you're doing." It would be better for clinicians to either directly ask HIV patients with an undetectable viral load about their drug adherence or assess pharmacy refills or both with every clinic visit. The study was supported in part by the Agency for Healthcare Research and Quality (HS10399). For more information on the CERTs program, please visit http://certs.hhs.gov/index.html.
More details are in "How long is the window of opportunity between adherence failure and virologic failure on efavirenz- Treatment failure may take up to 90 days after patients stop taking their antiretroviral medication as directed P atients suffering from rheumatoid arthritis (RA) and other rheumatologic diseases are often treated with disease-modifying antirheumatic drugs (DMARDs) to reduce their symptoms of fatigue, joint pain, and stiffness and to slow disease progression. However, State Medicaid programs are struggling to manage the costs of the newer biologic DMARDs, such as adalimumab and etanercept. A 1-month supply of these drugs may cost 100 times more than a year's supply of an older synthetic DMARD such as methotrexate or hydroxychloroquine. Many States have implemented prior authorization policies to limit use of biologic DMARDs. However, the policies vary, as do the clinical criteria patients must meet to be prescribed biologic DMARDs, according to a new study.
There are currently no clinical guidelines for when such medications should be started. In this study, 32 States required prior authorization for one or more biologic DMARDs. States varied in the specific medications covered and the criteria required for a drug to be authorized, note Michael A. Fischer, M.D., M.S., and Harvard Medical School colleagues. For example, some States required documentation that the patient had a prior inadequate response to one or more synthetic DMARDs, while others required the prescription be written by a rheumatologist (the toxicity of these drugs often requires complex monitoring).
The researchers obtained prior authorization policy information on biologic DMARDs from State Medicaid 
Health Care Costs and Financing
State Medicaid programs vary in prior authorization policies for use of costly biologic antirheumatic drugs T reatment of HIV infection with antiretroviral therapy (ART) saves lives, but longterm adherence to ART is critical to its success in halting disease progression. Blacks and young people are more likely than others to stop taking their ART early, while women are more likely than men to stop taking some ART drugs than others, concludes a new study. The researchers looked at the influence of sociodemographic factors on early discontinuation of ART among 3,654 black and white adults enrolled in the Tennessee Medicaid (TennCare) program. These patients began taking either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) between 1996 and 2003.
PIs can cause nausea, vomiting, and diarrhea soon after treatment starts, and NNRTIs are linked to rashes and drug-induced hepatitis, which can also occur early in therapy. The NNRTI efavirenz can cause insomnia, dizziness, and intense dreams. In this study, about one-third of the group with HIV disease who began ART containing a PI or NNRTI discontinued therapy within 6 months of starting it. Blacks were more likely than whites to discontinue NNRTIs (37 vs. 28 percent) and PIs (36 vs. 25 percent).
Black race, female sex, and younger age were independent predictors of discontinuation among those starting PIs. Among persons starting NNRTIs, black race, younger age, and disability (based on TennCare enrollment category) predicted early drug discontinuation, but female sex did not. These use patterns may be due to greater and more severe side effects of ART related to genetic differences among blacks and/or greater susceptibility to drug side effects among women than men, suggest the researchers. This study was funded in part by a grant from the Agency for Healthcare Research and Quality (HS10384) A s first responders, the emergency medical services (EMS) system delivers medical care in less than ideal settings outside of the hospital. Each year, 16 million patients are transported to emergency departments (EDs) in the United States. A variety of adverse events can occur, prompting legal action. A recent study found a low rate of medical carerelated claims against EMS providers; however, when claims are filed, they are most often related to mishaps involving EMS vehicles and the handling of patients.
Researchers retrospectively analyzed 326 EMS liability insurance claims data provided by a major insurer of EMS systems. In each case, the adverse event was categorized. Characteristics on the emergency units, injured individuals, and associated continued on page 21
Vehicle accidents and patient mishandling are the most common reasons for legal claims against emergency medical services W hen patients go to the emergency department (ED) with chest pain, more than half will not have coronary artery disease (CAD). Some patients are admitted to observation units (OUs) where physicians can rule out any problems in low-risk patients. This type of chest-pain evaluation is cost-effective compared with standard hospital admission. However, when low-risk patients complete their OU evaluation with a positive or indeterminate stress test, they are admitted to the hospital and often undergo cardiac catheterization with negative results (i.e., less than 50 percent stenosis, absence of threevessel disease, and no percutaneous intervention completed) which, in turn, significantly increases costs.
The researchers retrospectively studied the charts of 1,194 patients admitted to the OU over a period of 9 months. Chart reviews were conducted on all patients with positive and indeterminate stress tests and on a sample of patients with negative stress tests.
The majority of study patients (90.8 percent) had negative stress tests. Of the 59 patients who underwent cardiac catheterization, 41 were negative. The prevalence of positive or indeterminate stress tests with negative catheterization among all OU stress test patients was 3.4 percent. The prevalence of significant CAD at cardiac catheterization was 1.5 percent.
Costs increased across the board for patients with positive or indeterminate stress tests and subsequent negative catheterizations. When compared with costs for patients with negative stress tests, these patients had increases in ED ($520 vs. $467) and OU ($440 vs. $307) costs, total costs ($7,298 vs. $1,562), and total charges ($23,499 vs. $6,973) . The researchers indicate that studies are needed to determine the effectiveness and cost/benefit of other methods to risk stratify patients with lost-risk chest pain. The study was supported in part by the Agency for Healthcare Research and Quality (HS00078).
See "Diagnostic uncertainty and costs associated with current emergency department evaluation of low risk chest pain," by Rahul K. injuries were also identified. The analysis also included either an estimate of or the actual total incurred costs.
The most common adverse events identified were crashes of EMS vehicles and the mishandling of patients. Both of these categories accounted for more than 70 percent of the claims studied. In the crashrelated claims, those most often injured were pedestrians, bicycle riders, and the occupants of other vehicles. Patient handling mishaps most often involved dropping the patient. This was the result of stretcher collapse, dropping the stretcher or wheelchair, or dropping the patient during transfer. Among the clinical management adverse events, errors in airway management were the most common. Overall, a quarter of claimants either died or sustained a life-threatening or disabling injury.
The researchers point to the unique care elements associated with EMS. These include dispatch, response, patient extrication and movement, scene management, and transport. Efforts aimed at quality improvement in EMS must address these important and unique characteristics and not just the clinical aspects of care. The study was supported in part by the Agency for Healthcare Research and Quality (HS13628) .
See The researchers found that operating margin did not have a significant effect on the incidence of adverse events in the following areas: surgical-related patient safety events, nursing-related patient safety events, and in-house mortality for diagnosis-related groups with typically low mortality rates. However, the poorest and second poorest performing groups (hospitals were divided into quartiles) in relation to cash flow to total revenues did have higher excess incidents in two of these areas.
continued on page 24 T he Agency for Healthcare Research and Quality (AHRQ) released a pair of plain-language guides for consumers and clinicians comparing the efficacy, effectiveness, and side effects of newer premixed insulin analogues with conventional insulin (human insulin) and other preparations used to control Type 2 diabetes.
The consumer guide-Premixed Insulin for Type 2 Diabetes: A Guide for Adults-is a primer on diabetes, diabetes testing, and treatments. The guide explains the differences among insulin analogues that last all day, insulin used at meal time, and the newer premixed insulin analogues that are both effective all day and after meals, a time when blood sugar levels can suddenly rise. Finally, the guide offers a cost comparison chart for different types of treatments under generic and brand names.
The clinician guide-Premixed Insulin Analogues: A Comparison with Other Treatments for Type 2 Diabetes-covers the same information as the consumer guide, but also includes a level of confidence scale for the information included in the guide, based on the systematic review of literature and assists clinicians in choosing the appropriate type of insulin based on patients' physiologic needs.
The new guides on treatments for type 2 diabetes show that:
• When newer premixed insulin analogues were compared with long-acting insulin analogues (insulin lasting all day), the premixed insulin analogues were better at lowering A1c levels and at lowering blood sugar after meals. The long-acting insulin analogues were found to be better at lowering fasting blood sugar levels, and showed fewer incidents of hypoglycemia and less weight gain.
• When conventional insulin (premixed human insulin) was compared with newer premixed insulin analogues, the latter was better at lowering blood sugar after meals, but both kinds of insulin were equally as effective at lowering A1c and lowering fasting blood sugar levels. They showed similar incidence of hypoglycemia and weight gain. (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) . The study found that white men had a high risk of injury relative to the other groups (white women, black men, black women, Latino men, Latino women) and experienced the greatest decline over time. Among women, black women had the greatest risk of injury. Workers who moved into jobs requiring more work hours had increased odds of injury. Working in higher-wage jobs did not protect against injury; moreover, unionized jobs and jobs with health insurance were associated with increased injury odds. Finally, environmental hazards were associated with elevated injury risk but the level of physical demand was not associated with a higher risk of physical injury. Patient cost sharing is among the most commonly used levers to control health care costs. Therefore, efforts should be made to assess the extent to which cost sharing contributes to the failure of patients to receive high quality care. This study is the first to investigate the impact of cost sharing on the most widely used measures of performance contained in the Health Plan Effectiveness Data and Information Set (HEDIS). Specifically, the researchers focus on all of the HEDIS measures related to prescription medications. Their analysis uses the [2000] [2001] [2002] [2003] MarketScan Commercial Claims and Encounters database, which includes 6 million employees with employer-sponsored health insurance each year. Three types of patients were included: those with persistent asthma, those with a diagnosis of major depression, and those discharged from the hospital after a heart attack. Copayments for office visits or prescription drug payments had no appreciable effect on heart disease performance measures. By contrast, office visit copayments but not prescription drug copayments affected the asthma performance measure. The strongest copay effects were found for depression, where a $10 increase in copayments yielded a reduction of 3.6 percent in the performance measure. Under a policy rule that took effect in October 2008, the Centers for Medicare & Medicaid Services will stop paying hospitals the extra costs they incur for eight hospitalacquired conditions whose serious consequences, experts believe, could be prevented. This rule is a much-anticipated change in the Federal government's response to patient safety events. Aligning hospital payments with improved patient safety has also gained steam among private health care The researchers extend the twopart random effects model for clustered semi-continuous data to the multilevel setting. They apply a novel multilevel two-part model to the efficacy trial of topiramate for alcohol-dependent subjects. The estimation and inference are carried out through Gaussian quadrature technique, which is available in free software. The model takes into account the preponderance of zeros as well as the multilevel structure. The efficacy trial was conducted to compare the safety and efficacy of oral topiramate and placebo in a group of 150 alcohol-dependent subjects. When compared with the results of two simple models with respect to the positive number of drinks outcome, the novel model performed better in terms of Akaike information criteria. An important advantage of the new model is that it can be applied to other substance addiction studies because of its efficiency and simplicity. 
